GlaxoSmithKline plc 3.9% Potential Decrease Indicated by Deutsche Bank

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

GlaxoSmithKline plc using EPIC/TICKER code (LON:GSK) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ today by analysts at Deutsche Bank. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set a target price of 1645 GBX on its stock. This would imply the analyst believes there is a potential downside of -3.9% from today’s opening price of 1712 GBX. Over the last 30 and 90 trading days the company share price has increased 49.2 points and increased 173 points respectively. The 1 year high stock price is 1749.4 GBX while the 52 week low for the stock is 1408.8 GBX.

GlaxoSmithKline plc has a 50 day moving average of 1,668.45 GBX and the 200 Day Moving Average price is recorded at 1,576.88. There are currently 4,988,423,784 shares in issue with the average daily volume traded being 8,230,196. Market capitalisation for LON:GSK is £86,966,586,049 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage.
    GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges.
    GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025.

      Search

      Search